The Royal Melbourne Hospital’s Associate Professor Rosie Watson has received over $1.2 million dollars in federal government funding as Chief Investigator on an international project aimed at improving outcomes in dementia.
A/Prof Rosie Watson received a $1.2 million grant towards her COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT).
COBALT, to be run in 25 UK and 5 Australian sites is planned to run over four years and will see whether the drug memantine is an effective treatment option for patients with dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
Lewy body dementia, encompassing DLB and PDD is the second-most common form of neurodegenerative dementia in older people, second to Alzheimer’s.
A/Prof Watson’s funding is part of a $5.5 million government package for ten ground-breaking medical research projects aimed at improving outcomes in mental health, dementia, aged care, cerebral palsy, diabetes and more.
The funding allows RMH researchers to engage with world-leading researchers and allows to help translate scientific discoveries into real world outcomes internationally.
The Government’s funding contribution is part of the National Health and Medical Research Council’s commitment to international collaboration, and supports research grants awarded under joint schemes with the European Union and with the UK National Institute for Health Research.
Melbourne Health also congratulates the University of Melbourne’s Professor Colin Masters, who received a $498,412 grant for his study into Blood Proteins for early Discrimination of dEmentias (bPRIDE).